Site Editor

Sandy Srinivas, MD

Advertisement

Advertisement

Medical Literature

Is Adding Olaparib to Cediranib of Benefit in Metastatic Castration-Resistant Prostate Cancer?

News

Focused Treatment of Solitary Prostate Cancer Metastases Without Hormone Blockers

Medical Literature

VA Study Addresses the Impact of PSA Screening on Subsequent Metastatic Prostate Cancer

News

Prostate Cancer Cell Lines: Brazilian Berry Extract and Immune Responses

Medical Literature

Are Prostate Tumor Germline Mutations Linked to Genetic Ancestry?

News

Can Single-Port Robotic Surgery Improve Cosmesis After Prostate Surgery?

News

Novel Gene Signature May Predict the Risk of Lineage Plasticity in Prostate Tumors

Michael J. Morris, MD: Can Lutetium-177–PSMA-617 Plus Standard of Care Improve Outcomes in Advanced Prostate Cancer?

Peter C. Black, MD, on Improving Prostate Cancer Outcomes for Black Men

View More

Advertisement

JNCCN Spotlights

Lutetium Lu-177 Vipivotide Tetraxetan

(UPDATE September 2022) Enzalutamide

(UPDATE) Degarelix (Injectable GnRH Antagonist)

Docetaxel (Castration-Naive Metastatic Prostate Cancer)

UPDATE October 2020 Enzalutamide

Degarelix (Injectable GnRH Antagonist)

(UPDATE) Apalutamide in Prostate Cancer

View More

More

News

ASTRO 2022: Is There a Correlation Between PSA Screening and Subsequent Metastatic Prostate Cancer?

Comparison of Radiotherapies for Prostate Cancer: From the Phase III PACE Trial

Prostate Cancer Cell Lines: Brazilian Berry Extract and Immune Responses

ASTRO 2022: Salvage Radiotherapy Plus Enzalutamide for High-Risk Prostate Cancer After Prostatectomy

ASTRO 2022: Assessing Sexual Dysfunction After Brachytherapy for Genitourinary Cancers

Oligometastatic Prostate Cancer: Do Genomic Alterations Have Prognostic Value?

Novel Gene Signature May Predict the Risk of Lineage Plasticity in Prostate Tumors

ASTRO 2022: Using 24-Gene Score to Predict Outcomes With Salvage Radiotherapy After Radical Prostatectomy

View More

Advertisement

Published

Medical Literature

Researchers Offer Evidence That Prostate Cancer Biology May Differ by Racial Ancestry

Adding Darolutamide to Standard Treatment in Metastatic, Hormone-Sensitive Prostate Cancer

Enzalutamide Monotherapy: Active Surveillance Alternative in Low- or Intermediate-Risk Prostate Cancer?

Can the Number of Positive Pelvic Lymph Nodes Guide Adjuvant Radiation Therapy for Prostate Cancer?

View More

Ongoing

CE Activities

Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape

Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting

Talk to Someone: Explore Talking to Patients About Prostate Cancer Treatment

How Will You Manage These Patients With Prostate Cancer? Practice Your Skills in This Virtual Patient Simulation

View More

Available

Clinical Trials

University of Nebraska

Seidman Cancer Center

City of Hope

Dana-Farber Cancer Institute

View More

Resources

For Your Patients

Urology Care Foundation

Cancer Support Community

Prostate Cancer Foundation

NCCN Guidelines for Patients®: Prostate Cancer: Early Stage

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.